Eric Rowinsky, M.D. has served as the Chairman of Purple Biotech’s Board since October 2019. Dr. Eric Rowinsky’s principal expertise is in the development and registration of novel therapeutics to treat cancer and related disorders. Dr. Rowinsky currently serves as consulting Chief Medical Officer and/or advisor for drug development and registrational strategies to several biopharma companies worldwide. Dr. Rowinsky has served as the Chief Medical Officer of Hummingbird Biotherapeutics, a life-science company from 2016 to 2023. From 2015 to 2021, Dr. Rowinsky served as Executive Chairman of the Board of Directors and President of Inspira, Inc. (formerly Rgenix, Inc) and is currently serving as its President, Chairman of the Scientific Advisory Board, and Director. Dr. Rowinsky also served as the Chief Scientific Officer of Clearpath Development Inc., from 2015-2021, and has served as a consulting Chief Medical Officer of Oncotartis, Inc. since 2018 and as an advisor to Everest Medicines, Inc. since 2017. Dr. Rowinsky served as Executive Vice President, Chief Medical Officer and Head of Research and Development of Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, from November 2011 until October 2015. Prior to joining Stemline, Dr. Rowinsky was co-founder and Chief Executive Officer of Primrose Therapeutics, Inc., a start-up biotechnology company, from June 2010 until its acquisition in September 2011. Dr. Rowinsky also served as a drug development and regulatory strategy consultant to the ImClone-Lilly Oncology Business Unit and several other biopharmaceutical and life sciences companies from 2010 to 2011. From 2005 to 2009, Dr. Rowinsky was Executive Vice President and Chief Medical Officer of ImClone Systems Inc., where he led the FDA approval of Erbitux for head and neck and colorectal cancers and advanced eight other monoclonal antibodies through clinical development. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center, including Director of the Institute of Drug Development, or IDD, and the SBC Endowed Chair for Early Drug Development at the IDD. From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co-principal investigator from 1990 to 2004, and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numerous cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofusp and temsirolimus among others. Dr. Rowinsky was also an Adjunct Professor of Medicine at New York University School of Medicine (2008-2018). Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Fortress Biosciences, Inc., and Verastem Inc. Dr. Rowinsky formerly served on the boards of directors of the public companies Navidea Biopharmaceuticals Inc. (2010-2018), BIND Therapeutics (2014-2016), and Biophytis S.A. (2018-2019), as well as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York University (1977) and an M.D. degree from Vanderbilt University School of Medicine (1981). Dr. Rowinsky completed his residency in internal medicine at the University of California, San Diego (1984) and completed his fellowship in medical oncology at The Johns Hopkins Oncology Center (1987).

Isaac Israel has served as a member of our Board of Director since October 2012. Currently, Mr. Israel provides advisory services to the Company since July 2022. Prior to that, from October 2012 until July 2022, Mr. Israel served as the Company’s Chief Executive Officer. Mr. Israel was the founding Chief Executive Oficer of BeeContact Ltd. (formerly TASE:BCNT), from 2001 until 2007. Since 2008, Mr. Israel has served as founding Chief Executive Officer of Uneri Capital Ltd., a consulting firm in the capital markets field, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel served as a member of the board of directors and as chairman of the board of various private and public healthcare corporations.

Ido Agmon, MBA, has served as a member of Purple Biotech's Board since June 2016. Since 2012, Mr. Agmon has been acting as an independent consultant and investment manager, providing start-ups, investment funds and technology-based ventures with advice in strategic & financial planning, fund-raising and related business development activities. From 2014 until the end of 2016, Mr. Agmon was a manager of Aviv New-Tech (formerly Aviv Bio-Invest), a private investment fund which manages a portfolio of public Israeli & global biomed and technology companies, of which he was a co-founder, and where he was responsible for analysis and evaluation of investments in Israeli and global biomed companies. From 2009 until 2011, Mr. Agmon served as the CEO of Meytav Technology Incubator, an Israeli-based accelerator for biotech, pharma & medtech ventures with over 20 portfolio companies. Mr. Agmon has served as a board member at a number of biomed ventures. From 2007 until 2009, he worked as the Director of Business Development at ATI incubator, a technology incubator specializing in biomed and cleantech projects, responsible for deal-flow and project evaluation. Mr. Agmon holds a Bachelor’s Degree in Business Administration & Life Sciences from Tel Aviv University, Tel Aviv, Israel, and an MBA from The Hebrew University, Jerusalem, Israel.

Robert Gagnon has served as a member of Purple Biotech’s Board since March 2021. Mr. Gagnon currently serves as Chief Financial Officer of Remix Therapeutics. Prior to that, Mr. Gagnon was an Chief Financial Officer / Operating Partner of Gurnet Point Capital, a healthcare venture capital and private equity fund. Prior to joining Gurnet Point Capital in 2022, Mr. Gagnon was Chief Financial Officer / Chief Business Officer of Verastem Oncology. Before joining Verastem in 2018, Mr. Gagnon served as the Chief Financial Officer at Harvard Bioscience, Inc. Prior to that, Mr. Gagnon served as Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc., as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier in his career, Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP and PricewaterhouseCoopers, LLP. Mr. Gagnon holds an M.B.A. degree from the MIT Sloan School of Management and a B.A. degree in accounting from Bentley College. Mr. Gagnon is a board member of Verastem Oncology, Inc. and Bone Biologics, Inc.

Suzana Nahum-Zilberberg has served as a member of our Board of Directors since May 2021. Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd., Matricelf Ltd and Nextferm Technologies Ltd., all of which are traded on the Tel Aviv Stock Exchange, and a number of private companies. Prior to joining BioLight, Ms. Nahum-Zilberberg held a number of leadership positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO. Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.

Dr. Yael Margolin has served as a member of our Board of Directors since December 2023. Since 2019, Dr. Margolin has served as a board member to several public and private companies in the healthtech industry, including: Point Biopharma Global (NASDAQ: PNT), Scinai Immunotherapeutics (NASDAQ: SCNI), Quris AI, MakeSense, Neovac, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University. From 2005 to 2019, she served as President, Chief Executive Officer and director of Gamida Cell Ltd. (NASDAQ: GMDA), a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, she was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin is a founder of mentoring@8400, a boutique voluntary mentoring program for young CEOs in Israel. Dr. Margolin holds a BSc in biology and a MSc Cum Laude both from Tel Aviv University in Israel, a Ph.D. from the Weitzman Institute of Science in Israel and was a post-doctoral associate at the Yale University School of Medicine.

Gil Efron has served as our Chief Executive Officer since July 2022 and has served as a member of Purple Biotech’s Board since March 2026. Prior to that, Mr. Efron served as our President and Chief Financial Officer from June 2021 until July 2022. Prior to that, Mr. Efron served as our Deputy Chief Executive Officer and Chief Financial Officer, from October 2018. Prior to joining us, Mr. Efron served as Deputy CEO and CFO of Kamada Ltd., a NASDAQ and TASE dual-listed plasma-derived protein therapeutics company, from September 2011 to November 2017. Prior to that, Mr. Efron served as the CFO of NASDAQ listed RRsat Global Communications Ltd. (Nasdaq: RRST), from September 2005 to March 2011. Prior to that, Mr. Efron served in various finance executive positions. Mr. Efron holds a B.A. degree in Economics and Accounting and an M.A. degree in Business Administration from the Hebrew University of Jerusalem and was granted a certified public accountant’s license (non-active) in Israel.

Amir Horowitz, PhD is an Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. His research focuses on harnessing NK and CD8 T cells for antitumor effector functions and has demonstrated a novel immunotherapeutic target axis involving the interaction between HLA-E expressing tumor cells and NKG2A-positive NK and CD8 T cells, which suppresses immune responses in treatment-resistant patients. Dr. Horowitz and others have demonstrated that the HLA-E/NKG2A axis is a dominant inhibitory checkpoint pathway in solid tumors and metastasis.

Afshin Dowlati, MD, is an expert in the biology and clinical management of thoracic malignancies and has led the thoracic oncology program at Case Western Reserve University since 2000. His work bridges clinical practice and translational research, with a focus on target validation and drug development, and he is uniquely positioned to advance novel therapeutics from preclinical models into the clinic. A major focus of Dr. Dowlati's research is small cell lung cancer (SCLC), an area where progress has been limited due to an incomplete understanding of disease biology. He has established a robust research infrastructure, including a retrospective clinical-pathologic database of over 800 SCLC patients treated at his institution over more than 15 years. This resource is complemented by genomic and transcriptomic data, enabling identification of clinically relevant mutations associated with survival and treatment response. His team utilizes cell line and mouse models to investigate these genomic drivers and generate data to support future clinical trials. He is also a founding member of an SCLC consortium dedicated to advancing research and treatment in this field, and has recently initiated efforts to define molecular predictors of response to immune checkpoint inhibitors in SCLC.

Alexander Shoushtari, MD, is a highly regarded medical oncologist based in New York, New York. He specializes in treating melanoma, particularly acral, mucosal, and uveal types, and is known for his expertise in cell- and immune-based therapies. Dr. Shoushtari has extensive experience in various oncology fields and is Associate Attending Physician at Memorial Sloan Kettering Cancer Center (MSK), where he has the largest practice for treating patients with melanoma. He is also an Assistant Attending Physician at the same institution, where he focuses on melanoma treatment and research. Dr. Shoushtari is a board-certified medical oncologist and has been in practice for over 15 years, offering a wealth of knowledge and experience to his patients.

Max S. Topp, MD, is head of haematology and associate Professor for translational immunology at the medical clinic II at the Universitätsklinikum Würzburg, Germany. After completing his medical degree at the University of Berlin, Germany, he undertook residencies at the Free University of Berlin and the University of Tübingen, both in Germany, and a postdoctoral fellowship in immunotherapy at the Fred Hutchinson Cancer Research Center in Seattle, USA. He is board certified in internal medicine and hematology/oncology and was appointed as Associated Professor for Translational Immunology in 2011 and Head of Hematology in 2014 at the Universitätsklinikum Würzburg. Professor Topp's research interests are in immunotherapy, both bispecific antibody constructs and CAR-T cells of leukemia and lymphomas. In addition, he has been the principal investigator in numerous trials for acute lymphoblastic leukemia, Hodgkin's lymphoma and diffuse large B-cell lymphoma. He is also a steering committee member of the German ALL Study Group and the German Hodgkin Lymphoma Study Group.